Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos    GLPG   BE0003818359

GALAPAGOS (GLPG)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
86.75(c) 86.06(c) 85.94(c) 84.5(c) 85.67 Last
166 012 241 969 206 366 307 230 227 420 Volume
+0.78% -0.80% -0.14% -1.68% +1.38% Change
More quotes
Financials (€)
Sales 2017 162 M
EBIT 2017 -72,7 M
Net income 2017 -24,9 M
Finance 2017 1 200 M
Yield 2017 -
Sales 2018 216 M
EBIT 2018 -63,0 M
Net income 2018 20,9 M
Finance 2018 1 153 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 124,26
EV / Sales2017 19,1x
EV / Sales2018 14,6x
Capitalization 4 298 M
More Financials
Company
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies.It operates through the Research and Development and Fee-for-service segments.The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June... 
Sector
Biotechnology & Medical Research
Calendar
10/26 | 10:00pmEarnings Release
More about the company
Surperformance© ratings of Galapagos
Trading Rating : Investor Rating :
More Ratings
Latest news on GALAPAGOS
10/19 GALAPAGOS : Findings from Galapagos N.V. Has Provided New Data on Arthritis (Eff..
09/27 GALAPAGOS : and MorphoSys report first promising signs of clinical activity in a..
09/22 GALAPAGOS : increases share capital through warrant exercises
09/21 GALAPAGOS : increases share capital through warrant exercises
08/31 GALAPAGOS : New Findings from Galapagos N.V. Yields New Data on Medicinal Chemis..
08/10 Cyclicals and ex-divs send European shares to four-month low
08/10 GALAPAGOS : GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a..
08/10 GALAPAGOS : GLPG1690 halts disease progression in IPF patients
08/09 GALAPAGOS : GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a..
07/28 GALAPAGOS : Servier licenses GLPG1972 in osteoarthritis from Galapagos
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/16Goldman Sachs Group Inc. Acquires 1,235 Shares of Galapagos NV $GLPG  
10/14Galapagos NV $GLPG Lifted to “Hold” at Zacks Investment Research  
10/13Galapagos NV $GLPG Stock Rating Upgraded by Zacks Investment Research  
10/12$GLPG - Galapagos NV #GLPG Upgraded at Zacks Investment Research  
10/12Galapagos NV upgraded by Zacks Investment Research to hold.  
More tweets
Qtime:78
News from SeekingAlpha
09/28 AbbVie Transitions To Growth Stock From Income Play
09/20 Why Gilead May Regain Growth Stock Status
09/16 Faison's Weekend Review And Scans
09/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 81-Stock August Portfolio Update - Buying..
09/15 Premarket analyst action - healthcare
Chart GALAPAGOS
Duration : Period :
Galapagos Technical Analysis Chart | GLPG | BE0003818359 | 4-Traders
Technical analysis trends GALAPAGOS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 93,6 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS41.02%5 157
INCYTE CORPORATION13.96%24 254
QUINTILES IMS HOLDINGS INC33.89%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.15%19 730
ALNYLAM PHARMACEUTICALS, INC.208.84%10 783